This report followed a defined subgroup
The longer SURMOUNT-1 analysis concerned 1,032 participants who had both obesity and prediabetes. They received assigned tirzepatide or placebo for 176 weeks, followed by 17 weeks off treatment. The original randomization was retained, but this report’s population was narrower than the entire initial trial. [1]
The distinction changes how a prevention headline should be read. It is evidence in people who already met the study’s prediabetes criteria, not a direct test of universal prevention in the general population. The relevant starting risk is part of the finding.
Diagnoses during and after treatment
By 176 weeks, type 2 diabetes was diagnosed in 1.3% of the pooled tirzepatide groups and 13.3% of the placebo group. After the off-treatment period, the reported proportions were 2.4% and 13.7%. Gastrointestinal events were the most common non-COVID adverse events, generally mild or moderate. [1]
The two time points are useful because they keep observation during treatment separate from observation after withdrawal. A result measured while a medicine is being taken does not automatically establish permanent protection after it ends. The additional follow-up extends the evidence, but only by the period actually observed.
Absolute numbers help interpret a dramatic relative result
Using the reported 176-week proportions, the difference is 12 percentage points: 13.3 minus 1.3. That arithmetic is a way of describing the observed trial groups. It is not a personal risk calculator, because an individual’s starting risk and treatment circumstances may differ.
A hazard ratio, a cumulative percentage and a lifetime probability are also different quantities. A headline can move between them without making the change obvious. Preserve the original endpoint and time horizon when discussing the result; do not translate fewer diagnoses during follow-up into a claim that diabetes is impossible.
The pooled treatment percentage is also not a separate estimate for each tirzepatide target dose. Pooling can make the headline easier to communicate while answering a broader comparison. A consumer should avoid assigning the pooled prevention estimate to a specific personal regimen without an appropriate analysis supporting that step.
Questions for someone with prediabetes
Ask which of your measured risk factors inform the treatment discussion and how the clinician plans to reassess them. Clarify whether the conversation concerns weight management, glucose monitoring or both. A favorable research result does not remove the need to define the clinical goal.
Our STEP 10 analysis examines a different endpoint: return to a specified normal-glucose category. It should not be treated as identical to counting diabetes diagnoses over several years. For continuing-care planning, use the maintenance guide to discuss the practical time horizon alongside the evidence.